arrow
K

Kazuma Kiyotani

national institutes of biomedical innovation, health and nutrition
H指数:46
被引数:6,375

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma

外周B细胞受体库预测免疫检查点抑制剂治疗晚期肾细胞癌后的免疫相关不良事件

2026-07-060
OA
Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor responders

日本患者黑色素瘤的基因组与转录组分析揭示了免疫检查点抑制剂应答者的候选生物标志物

2026-01-070
OAAI
Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study

新抗原肽负载的树突状细胞疫苗疗法在胰腺癌手术治疗后:一项回顾性研究

2025-04-030
OA
Genomic and transcriptomic analysis of Japanese melanoma reveals candidate biomarkers for immune checkpoint inhibitor responders

日本黑色素瘤的基因组学和转录组学分析揭示了免疫检查点抑制剂应答者的候选生物标志物

2024-09-010
PRE
Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy

APC基因突变通过激活WNT信号通路介导免疫逃逸,对接受曲妥珠单抗(tmab)、纳武利尤单抗(nivo)和化疗治疗的HER2阳性胃癌患者生存的影响。

2024-09-010
PRE
Clinical landscape of TP73 structural variants in ATL patients
LEUKEMIA
IF13.4
2023-10-201
OAAI
Clinical Impact of ERBB2 copy number and tumor mutation burden (TMB) in patients with HER2-positive advanced gastric cancer treated by nivolumab (N-mab) plus trastuzumab (T-mab) and standard chemotherapy
2023-10-010
PRE
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
2022-04-1416
OAAI